Novo halts once-monthly obesity drug as part of strategic reset
The company rebranded as 'Novo' and discontinued development of a once-monthly obesity treatment.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 15 22:25 ETSource: finance.biggo.com
The wire
- 01Novo Nordisk rebranded to 'Novo' and halted its once-monthly obesity drug program in a strategic reset.
- 02Dropping a long-acting obesity candidate narrows Novo's next-generation pipeline against rivals.
- 03Reasons for the discontinuation and remaining pipeline priorities were not detailed.
From the source
Read at news.google.comNovo Nordisk Rebrands as 'Novo' and Halts Once-Monthly Obesity Drug in Strategic Reset